PRP vs. Cortisone Injections: Mechanism, Duration, and Patient Outcomes

When a joint flares up or a tendon becomes inflamed, two of the most common injection-based options a physician might discuss are cortisone and platelet-rich plasma (PRP). Both are delivered directly into the affected area. Both can reduce pain. But their mechanisms, timelines, and long-term effects on tissue are fundamentally different, and understanding those differences can help patients have more productive conversations with their physicians.

This article walks through how each injection works at the biological level, what the published research suggests about their relative duration of benefit, how they compare on risk profile, and which patients tend to be better candidates for each approach.

How Cortisone Injections Work

Anti-Inflammatory Mechanism

Cortisone injections deliver a corticosteroid compound, typically triamcinolone, methylprednisolone, or dexamethasone, directly into an inflamed joint, bursa, or soft tissue structure. These synthetic steroid molecules mimic the body’s own cortisol and work by binding to glucocorticoid receptors inside cells, which then travel to the cell nucleus and alter gene expression.

The downstream effect is broad suppression of the inflammatory cascade. Corticosteroids inhibit phospholipase A2, the enzyme that initiates the arachidonic acid pathway. By blocking this step, they reduce the production of prostaglandins and leukotrienes, two classes of molecules that drive the redness, swelling, heat, and pain associated with tissue inflammation. Corticosteroids also suppress the synthesis of multiple pro-inflammatory cytokines, including interleukin-1 and tumor necrosis factor, which are key signaling molecules that recruit immune cells to damaged tissue.

The result is rapid, predictable anti-inflammatory relief. Because the suppression happens at multiple points in the inflammatory cascade, cortisone works even when the underlying trigger varies, whether the cause is mechanical irritation, autoimmune activity, or overuse.

Typical Duration of Relief and Repeat Use Considerations

Most patients experience meaningful pain relief within 24 to 72 hours of a cortisone injection. Clinical evidence indicates that significant improvement typically lasts between four and twelve weeks, though individual responses vary widely. Some patients report relief that extends beyond this window, while others notice effects wearing off in two to three weeks.

A well-documented concern in the orthopedic literature is diminishing returns with repeated injections. Research suggests that each successive cortisone injection to the same joint tends to produce a shorter and less robust period of relief. More significantly, multiple published studies have raised concerns about the cumulative effect of repeated corticosteroids on cartilage health. A series of studies, including imaging-based research published in journals such as Radiology, found associations between frequent intra-articular corticosteroid injections and accelerated cartilage thinning, with some analyses showing measurable joint space loss over time compared to controls.

Corticosteroids also affect soft tissue. Multiple studies have documented tendon-weakening effects when steroids are injected in proximity to tendon tissue, which is one reason most guidelines recommend caution with peritendinous injections. The general clinical consensus recommends limiting corticosteroid injections to no more than three to four per year in any single joint, and many physicians advise spacing injections at least six to eight weeks apart. Chronic exposure to corticosteroids locally can impair the body’s natural repair signaling, thin the synovial lining, and reduce the quality of joint fluid over time.

How PRP Injections Work

Growth Factor Delivery and the Healing Signal

Platelet-rich plasma is prepared from a patient’s own blood. A sample is drawn and then spun in a centrifuge to concentrate the platelet layer, which is separated and used for injection. The resulting PRP preparation contains a concentration of platelets that is typically three to eight times higher than whole blood, depending on the preparation protocol.

Platelets are not just clotting agents. When activated, they release a range of signaling proteins from structures called alpha granules. These include platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-beta), vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and insulin-like growth factor (IGF-1). Each of these molecules plays a distinct role in the tissue repair process.

PDGF signals fibroblasts to proliferate and migrate into the repair zone. TGF-beta promotes extracellular matrix synthesis, including collagen deposition in tendons and proteoglycan production in cartilage. VEGF stimulates new blood vessel formation, which is critical for tissue that has poor baseline circulation. EGF supports epithelial and connective tissue repair.

Importantly, PRP’s anti-inflammatory effect operates through a different mechanism than cortisone. Rather than broadly suppressing the immune response, PRP modulates the inflammatory environment. It can reduce certain pro-inflammatory cytokines while promoting the transition from the inflammatory phase to the proliferative and remodeling phases of healing. Research suggests this modulation, rather than suppression, leaves the body’s repair systems intact while still addressing the pain-generating inflammatory signals.

Why PRP Takes Longer to Show Effect

Because PRP works by initiating biological processes rather than chemically blocking a pathway, the timeline of response is fundamentally different. Tissue remodeling, new collagen synthesis, and chondrocyte proliferation are cellular processes that unfold over weeks, not hours.

In many cases, patients may actually experience a temporary increase in soreness in the first one to two weeks following PRP injection. This is a normal part of the process: the platelet activation triggers a localized inflammatory response as the healing cascade begins. This initial flare is not a sign that the treatment is failing; it is often considered evidence that the biological signaling is active.

Clinical evidence and patient-reported outcomes consistently place the onset of meaningful PRP benefit at four to eight weeks post-injection, with peak benefit often seen at three to six months. Setting this expectation before treatment is essential. Patients who do not understand this timeline may interpret the early soreness or the absence of rapid relief as a sign the injection did not work, when in fact the tissue repair process is underway.

Side-by-Side Comparison

Speed of Relief

Cortisone typically produces noticeable symptom reduction within one to three days of injection. PRP improvement generally becomes apparent at four to eight weeks post-procedure.

For patients who have an acute, time-sensitive need, such as an important athletic event, a work obligation, or a significant life event approaching within a few weeks, this difference matters clinically. Cortisone can provide a functional bridge in ways that PRP cannot replicate in a compressed timeframe.

Duration of Effect

Published evidence consistently shows that cortisone’s benefit curve declines over time, with most relief concentrated in the first four to twelve weeks. PRP, by contrast, produces improvement that in many cases extends significantly longer.

Multiple randomized controlled trials comparing PRP to cortisone in knee osteoarthritis have shown PRP to be superior at six and twelve month follow-up. One prospective randomized controlled study found that at one year, patients in the PRP group had a mean VAS (Visual Analog Scale) pain score reduction of 52 percent from baseline, compared to 14 percent in the corticosteroid group, a statistically significant difference. At shorter timepoints, cortisone often showed superior outcomes, reflecting its faster onset and early dominance.

For shoulder conditions including periarthritis and rotator cuff tendinopathy, research suggests a similar pattern. Corticosteroid groups frequently show better outcomes at six to twelve week marks, while PRP groups tend to achieve better pain and disability scores at six months and beyond.

Risk Profile

Cortisone carries a well-established list of risks. Cartilage thinning with repeated injections is supported by imaging studies. Tendon weakening with peritendinous injections is documented in the literature. Systemic effects can include transient blood glucose elevation, which is a meaningful consideration in diabetic patients, as well as temporary adrenal suppression with frequent use. Local infection risk is low when proper sterile technique is used but is not zero.

PRP carries a different risk profile. Because it is prepared from the patient’s own blood (autologous), the risk of allergic reaction or immune rejection does not apply. Infection risk is low with proper technique. The most common reported side effect is a temporary pain flare in the first one to two weeks, which typically resolves. No known systemic effects have been documented with autologous PRP. From a tissue impact standpoint, PRP appears to have a neutral to potentially positive effect on the tissue into which it is injected, in contrast to the dose-dependent tissue risks associated with repeated cortisone.

This favorable risk profile is one reason PRP is increasingly considered appropriate for patients who may need more than one treatment session or who are managing a long-term condition.

Cumulative Impact on Tissue

The cumulative effects of cortisone on joint cartilage are now an established area of clinical concern. While a single well-timed cortisone injection in a symptomatic joint may be entirely appropriate, a pattern of repeated injections over years may accelerate the degenerative process that patients are trying to slow. This does not mean cortisone is contraindicated for ongoing use, but it does mean that the decision to repeat injections should be made with an awareness of the tissue tradeoffs involved.

PRP, in contrast, is not associated with cartilage thinning or tendon weakening in the published literature. Some research suggests it may support the integrity of the cartilage matrix over time. For patients managing early to moderate osteoarthritis who are thinking about treatment over a multi-year horizon, the cumulative tissue impact of each approach is a relevant consideration.

Which Patients Tend to Benefit from Each

When Cortisone Makes Clinical Sense

Cortisone remains a valuable clinical tool in specific circumstances. Patients experiencing an acute severe inflammatory flare, where pain and swelling are limiting basic function, may benefit from rapid cortisone relief while a longer-term strategy is developed. Patients who need to perform at a high level in the near term, such as before an important athletic event or a demanding work obligation, may find cortisone provides the functional window they need.

Cortisone also makes sense for patients who are not candidates for the timeline that PRP requires, whether due to difficulty tolerating delayed-onset relief, logistical limitations, or conditions where biological repair is not the primary treatment goal. In certain acute inflammatory conditions, such as gout flares or reactive arthritis, the broad anti-inflammatory suppression that cortisone provides aligns well with what is needed.

When PRP Is the Better Long-Term Option

PRP tends to be a better fit for patients whose primary goal is durable improvement rather than temporary relief. Younger patients who want to avoid accumulating cartilage exposure to repeated corticosteroids are one important group. Patients with early to moderate osteoarthritis, where meaningful cartilage and synovial tissue remain, may be better served by an approach that supports the existing tissue rather than one that may accelerate its degradation over time.

Tendinopathy is a condition where the cortisone-versus-PRP decision is particularly well-studied. Research in tendinopathies such as lateral epicondylitis, patellar tendinopathy, and rotator cuff tendinopathy has consistently shown that while cortisone may produce better short-term results, PRP groups tend to show superior outcomes at six to twelve months. Given the documented tendon-weakening concern with peritendinous corticosteroid injections, PRP is increasingly favored in protocols for tendon pathology.

Patients who prefer a biological rather than suppressive approach to their musculoskeletal condition, and who are willing to work through the initial recovery period and the four to eight week onset timeline, are generally good candidates for PRP.

Using Both in a Sequential Treatment Plan

Some treatment protocols use cortisone and PRP in sequence. In this approach, a cortisone injection is administered first to address an acute, severe flare and restore functional range of motion. Once the patient has stabilized, PRP is then delivered to begin the biological repair process.

The timing of this sequence requires physician oversight. Research suggests that corticosteroids may blunt the biological activity of PRP if the two are given too close together, as the broad immune suppression from cortisone may interfere with the growth factor signaling that PRP depends on. Most protocols that use both recommend allowing at least four to six weeks between cortisone administration and PRP injection to permit the steroid effect to diminish before introducing the PRP.

This kind of sequencing requires a physician who understands both mechanisms and can guide patients through the transition. When managed carefully, it allows patients to receive the rapid relief cortisone provides while also initiating the longer-arc biological repair that PRP supports.

Sources

Disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. This content is not a substitute for consultation with a qualified, licensed healthcare provider. Regenerative medicine procedures vary in outcomes based on individual health status, condition severity, and other clinical factors. No specific results are guaranteed. Consult a board-certified physician to determine whether any treatment discussed here is appropriate for your situation.